ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

GIGA-2339

A development code.

Its studies are mostly in Hepatitis B, led by Grifols.

Furthest: phase 1, since Apr 30, 20251 company-led study, 1 open or runningNext primary completion: Nov 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Grifols11 open or runningphase 1since Apr 30, 2025Apr 30, 2025Nov 2028phase 1 · NCT07024641

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 30, 2025First study: phase 1 study in Hepatitis BFirst studyNCT07024641 · 48 planned · United States, Australia, Hong Kong and more

Ahead

  1. Nov 2028Primary completion: phase 1 study in Hepatitis BNCT07024641

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07024641Hepatitis B · United States, Australia, Hong Kong and more1RecruitingNov 202848

How it is read

Names in the registry

  • “GIGA-2339”, 1 entry

Codes read as this program: GIGA2339.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.